Description
The G9P3 monoclonal antibody specifically recognizes mouse EVA1, which is encoded by the Mpzl2 gene. EVA1 is a member of the immunoglobulin-like cell-adhesion molecule (Ig-CAM or IgSF CAM) family, members of which are anchored to the surface of epithelial and endothelial cells via a GPI domain. This class of adhesion molecules interacts intracellularly with cytoskeletal proteins and extracellularly with Ig-CAM family members, by homophilic or heterophilic binding, and with other classes of adhesion molecules such as integrins and cadherins. EVA1 is expressed on and is involved in the structural integrity of epithelia throughout the body, eg mammary glands, liver, inner ear, and the blood-brain barrier. In the thymus, EVA1 is expressed both on thymic epithelial cells (TECs) and on a subset of developing thymocytes, known as DN3. It is a low-affinity mediator of developmental signals between thymocytes and TEC that support the differentiation and survival of both developing thymocytes and the TECs. G9P3 mAb was produced in EVA1 knockout mice immunized with recombinant mouse EVA1 extracellular region, and it recognizes mouse and human EVA1 expressed on transfected cells.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant Violet 786 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
10. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
Specifications

General

SourceMouse IGFBP-6, amino acids (Gly24-Gly238) (Accession# NM_008344), was expressed in 293E cells. The amino-terminal possesses a Met.
Molecular MassThe 216 amino acid recombinant protein has a predicted molecular mass of approximately 22.9 kD. The protein migrates at approximately 30-35 kD in both DTT-reducing and non-reducing conditions by SDS-PAGE. The predicted N-terminal amino acid is Met.
Purity>95%, as determined by Coomassie stained SDS-PAGE.
Formulation0.22 µm filtered protein solution is in 0.1% TFA, <30% ACN.
Endotoxin LevelLess than 0.01 ng per µg cytokine as determined by the LAL method.
Concentration10 and 25 µg sizes are bottled at 200 µg/mL.
Storage & HandlingUnopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
ActivityED50 = 0.1 - 0.5 µg/ml as determined by the inhibition of MCF-7 cell proliferation induced by mouse IGF-II (30 ng/ml, Cat. No. 588204).
ApplicationBioassay
Application NotesBioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
StructureMonomer.
DistributionIGFBP-6 is expressed in ovarian cells, prostatic cells, and fibroblasts. It is found predominantly in cerebral spinal fluid and serum.
FunctionThe protein binds preferentially to IGF-II over IGF-I and regulates their activity. It takes part in osteoblast differentiation, cancer, and angiogenesis. Retinoic acid increases IGFBP-6 expression in human osteoblast cells.
InteractionOsteoblasts, ovarian cancer cells, and rhabdomyosarcoma cells.
Ligand/ReceptorIGF-I, IGF-II, vitamin D receptor, and thyroid hormone receptor alpha 1.
BioactivityMouse IGFBP-6 inhibits the proliferation of MCF-7 cells induced by mouse IGF-II.
Cell TypeHematopoietic stem and progenitors, Mesenchymal Stem Cells
Biology AreaAngiogenesis, Cancer Biomarkers, Cell Biology, Cell Proliferation and Viability, Stem Cells
Antigen References1. Kelley KM, et al. 1996. Int. J. Biochem. Cell Biol. 28:619. 2. Brewer MT, et al. 1988. Biochem. Biophys. Res. Commun. 152:1289. 3. Murphy LJ, et al. 1998. J. Mol. Endocrinol. 21:97. 4. Ferry RJ, et al. 1999. Horm. Res. 51:53. 5. Cui J, et al. 2011. Mol. Cell Endocrinol. 338:84. 6. Qiu J, et al. 2012. Mol. Cell Biochem. 361:197. 7. Fu P, et al. 2013. J. Biol. Chem. 288:29890. 8. Bach LA, et al. 2013. Clin. Sci. 124:215. 9. Yang Z and Bach LA. 2014. Front Endocrinol. (Lausanne) 5:231.
Gene ID16012
UniProtView information about IGFBP-6 on UniProt.org
Regulatory StatusRUO
Other NamesInsulin-like growth factor binding protein 6 (IBP6), IGFBP6